A randomized phase II trial of adjuvant galinpepimut-S, WT-1 analogue peptide vaccine, after multimodality therapy for patients with malignant pleural mesothelioma

Clinical Cancer Research

Volumn 23, Issue 24, 2017, Pages 7483-7489

  Zauderer, Marjorie G ^a   Tsao, Anne S ^b   Dao, Tao ^a   Panageas, Katherine ^a   Lai, W Victoria ^a   Rimner, Andreas ^a   Rusch, Valerie W ^a   Adusumilli, Prasad S ^a   Ginsberg, Michelle S ^a   Gomez, Daniel ^b   Rice, David ^b   Mehran, Reza ^b   Scheinberg, David A ^a   Krug, Lee M ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CANCER VACCINE; GALINPEPIMUT S; GM CSF AGENT; MONTANIDE; UNCLASSIFIED DRUG; CISPLATIN; IMMUNOLOGICAL ADJUVANT; PEMETREXED; SUBUNIT VACCINE;

ADJUVANT THERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTHRALGIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; INJECTION SITE REACTION; LYMPHOCYTOPENIA; MALE; MULTIMODALITY CANCER THERAPY; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT OUTCOME; CLINICAL TRIAL; DISEASE FREE SURVIVAL; IMMUNOLOGY; LUNG TUMOR; MESOTHELIOMA; MIDDLE AGED; PATHOLOGY; PLEURA TUMOR; VERY ELDERLY;

ADJUVANTS, IMMUNOLOGIC; ADULT; AGED; AGED, 80 AND OVER; CISPLATIN; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PEMETREXED; PLEURAL NEOPLASMS; VACCINES, SUBUNIT;

EID: 85038565260     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-17-2169     Document Type: Article

References (25)

1. Vogelzang NJ, Rusthoven JJ, Symanowski J, Denham C, Kaukel E, Ruffie P, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636–44.
2. Rimner A, Zauderer MG, Gomez DR, Adusumilli PS, Parhar PK, Wu AJ, et al. Phase II study of hemithoracic intensity-modulated pleural radiation therapy (IMPRINT) as part of lung-sparing multimodality therapy in patients with malignant pleural mesothelioma. J Clin Oncol 2016;34: 2761–8.
3. Mundlos S, Pelletier J, Darveau A, Bachmann M, Winterpacht A, Zabel B. Nuclear localization of the protein encoded by the Wilms' tumor gene WT1 in embryonic and adult tissues. Development 1993;119:1329–41.
4. Amin KM, Litzky LA, Smythe WR, Mooney AM, Morris JM, Mews DJ, et al. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344–56.
5. Inoue K, Ogawa H, Sonoda Y, Kimura T, Sakabe H, Oka Y, et al. Aberrant overexpression of the Wilms tumor gene (WT1) in human leukemia. Blood 1997;89:1405–12.
6. Keilholz U, Menssen HD, Gaiger A, Menke A, Oji Y, Oka Y, et al. Wilms' tumour gene 1 (WT1) in human neoplasia. Leukemia 2005;19:1318–23.
7. Oji Y, Ogawa H, Tamaki H, Oka Y, Tsuboi A, Kim EH, et al. Expression of the Wilms' tumor gene WT1 in solid tumors and its involvement in tumor cell growth. Jpn J Cancer Res 1999;90:194–204.
8. Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003;17:1301–12.
9. Cheever MA, Allison JP, Ferris AS, Finn OJ, Hastings BM, Hecht TT, et al. The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research. Clin Cancer Res 2009;15: 5323–37.
10. Pinilla-Ibarz J, May RJ, Korontsvit T, Gomez M, Kappel B, Zakhaleva V, et al. Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein. Leukemia 2006;20: 2025–33.
11. Krug LM, Dao T, Brown AB, Maslak P, Travis W, Bekele S, et al. WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer. Cancer Immunol Immunother 2010;59:1467–79.
12. May RJ, Dao T, Pinilla-Ibarz J, Korontsvit T, Zakhaleva V, Zhang RH, et al. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4þ and CD8þ T cells that recognize and kill human malignant mesothelioma tumor cells. Clin Cancer Res 2007;13:4547–55.
13. Maslak PG, Dao T, Krug LM, Chanel S, Korontsvit T, Zakhaleva V, et al. Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia. Blood 2010;116:171–9.
14. Byrne MJ, Nowak AK. Modified RECIST criteria for assessment of response in malignant pleural mesothelioma. Ann Oncol 2004;15:257–60.
15. Rice D, Rusch V, Pass H, Asamura H, Nakano T, Edwards J, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the international association for the study of lung cancer international staging committee and the international mesothelioma interest group. J Thorac Oncol 2011;6: 1304–12.
16. Rosenzweig KE, Zauderer MG, Laser B, Krug LM, Yorke E, Sima CS, et al. Pleural intensity-modulated radiotherapy for malignant pleural mesothelioma. Int J Radiat Oncol Biol Phys 2012;83:1278–83.
17. Gaiger A, Carter L, Greinix H, Carter D, McNeill PD, Houghton RL, et al. WT1-specific serum antibodies in patients with leukemia. Clin Cancer Res 2001;7:761s–5s.
18. Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22:3451–7.
19. Rea F, Marulli G, Bortolotti L, Breda C, Favaretto AG, Loreggian L, et al. Induction chemotherapy, extrapleural pneumonectomy (EPP) and adju-vant hemi-thoracic radiation in malignant pleural mesothelioma (MPM): feasibility and results. Lung Cancer 2007;57:89–95.
20. Weder W, Stahel RA, Bernhard J, Bodis S, Vogt P, Ballabeni P, et al. Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. Ann Oncol 2007; 18:1196–202.
21. Batirel HF, Metintas M, Caglar HB, Yildizeli B, Lacin T, Bostanci K, et al. Trimodality treatment of malignant pleural mesothelioma. J Thorac Oncol 2008;3:499–504.
22. Bolukbas S, Manegold C, Eberlein M, Bergmann T, Fisseler-Eckhoff A, Schirren J. Survival after trimodality therapy for malignant pleural mesothelioma: radical pleurectomy, chemotherapy with cisplatin/pemetrexed and radiotherapy. Lung Cancer 2011;71:75–81.
23. Krug LM, Pass HI, Rusch VW, Kindler HL, Sugarbaker DJ, Rosenzweig KE, et al. Multicenter phase II trial of neoadjuvant pemetrexed plus cisplatin followed by extrapleural pneumonectomy and radiation for malignant pleural mesothelioma. J Clin Oncol 2009;27:3007–13.
24. Van Schil PE, Baas P, Gaafar R, Maat AP, Van de Pol M, Hasan B, et al. Trimodality therapy for malignant pleural mesothelioma: results from an EORTC phase II multicentre trial. Eur Respir J 2010;36:1362–9.
25. Hasani A, Alvarez JM, Wyatt JM, Bydder S, Millward M, Byrne M, et al. Outcome for patients with malignant pleural mesothelioma referred for Trimodality therapy in Western Australia. J Thorac Oncol 2009;4:1010–6.